KPC Pharmaceuticals Inc banner

KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 8.11 CNY 1.37% Market Closed
Market Cap: ¥6.1B

Wall St Price Targets

Price Forecast
Based on 3 analysts

+74% Upside
from ¥8.11 today

KPC Pharmaceuticals Inc (600422)’s 12-month stock price forecast through September 2027 has a consensus target of ¥14.1, implying 74% upside. The forecast is based on price targets from 3 Wall Street analysts.

Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for KPC Pharmaceuticals Inc yet.

KPC Pharmaceuticals Inc Competitors:
Price Targets

Financial forecasts

Past growth per year

Average annual growth cannot be calculated for these periods.

Explore analyst estimates, growth and forecast ranges.

Reported Lowest–highest estimate

Value YoY Lowest–highest Analysts
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is KPC Pharmaceuticals Inc's stock price target?
Price Target
14.1 CNY

According to Wall Street analysts, the average 1-year price target for KPC Pharmaceuticals Inc is 14.1 CNY with a low forecast of 13.96 CNY and a high forecast of 14.51 CNY.

What is the Revenue forecast for KPC Pharmaceuticals Inc?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 3%.

What is the Operating Income forecast for KPC Pharmaceuticals Inc?
Projected CAGR
24%

Over the last 13 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 3 years is 24%.

What is the Pre-Tax Income forecast for KPC Pharmaceuticals Inc?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 7%.

What is the Net Income forecast for KPC Pharmaceuticals Inc?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Net Income has been 5%. The projected CAGR for the next 3 years is 7%.

Back to Top